MetaVia (MTVA) Preferred Stock Liabilities (2015 - 2023)

MetaVia's (MTVA) quarterly Preferred Stock Liabilities came in at $975000.0 in Q2 2023, down 89.68% on a QoQ basis from $9.4 million in Q1 2023.

MetaVia (MTVA) Preferred Stock Liabilities (2015 - 2023) Analysis & Trends

MetaVia (MTVA) has 5 years of Preferred Stock Liabilities data on file, last reported at $975000.0 in Q2 2023.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $975000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $975000.0 (changed N/A YoY) and the FY2022 annual result came in at $10.8 million, changed N/A from the prior year.
Preferred Stock Liabilities declined to $975000.0 in Q2 2023, from $9.4 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $10.8 million in Q4 2022 to a low of $975000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	MetaVia	8.72 Mn	-3.92 Mn	-	-

Download Data